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Measuring dystrophin—faster is not necessarily better
Virginia Arechavala-Gomeza, Lucy Feng, Jennifer E. Morgan and Francesco
MuntoniA Research Highlight in the February issue (A novel imaging method to quantify low levels)1 presentedof dystrophin in Duchenne muscular dystrophy. Nat. Rev. Neurol. 8, 120; 2012findings on a new method for rapid dystrophin quantification in Duchenne musculardystrophy (DMD)2. Although of interest, we believe that caution is required in theinterpretation of dystrophin measurements obtained using this new technique.DMD is caused by the deficit of dystrophin protein at sarcolemma of muscle fibres3.Quantification of dystrophin on muscle biopsies is the main diagnostic test for DMDwhen genetic testing is unavailable. Several therapeutic approaches in DMD aim torestore dystrophin expression: redirection of splicing with antisense oligonucleotides;4,5 gene therapy6; stem cell therapy;7 and nonsense mutation read-through.8, 9 Precisequantification of dystrophin protein in muscle biopsies taken before and after treatmentis crucial to evaluate the biochemical success of the therapeutic intervention.Until recently, counting dystrophin positive fibres or western blotting were the onlyquantitative methods available, but researchers preparing for the first trials developeda method to sensitively quantify dystrophin and other associated proteins in the musclefibre sarcolemma using only two muscle sections per antibody.10 The method usesintensity measurements from fluorescently labelled dystrophin antibodies and spectrinlabelling as a normalising factor. The technique greatly advanced dystrophinquantification owing to its sensitivity, requirement for very little sample, capacity toconfirm the correct localization of the protein at sarcolemma, and accessibility to mostpathology laboratories. Despite being labour intensive, this method has been used in theanalysis of several clinical trials,4, 5 and in human11-13 and mouse14, 15 studies.Aided by a new spectrin antibody that enabled immunostaining for dystrophin andspectrin on the same section, researchers have been able to automate this technique2,which should accelerate the analysis of muscle biopsies in ongoing clinical trials.Despite the unequivocal advance that this method entails, one should note the potentialdrawbacks. One important aspect is that the original method involves collection of up to40 data points per section, each corresponding to a muscle fibre, whereas the recentmodification involves collecting an average dystrophin intensity of the whole image. Foraverages or multiple measurements in sections from a manifesting carrier, a clearsegregation of measurements is immediately evident using the original method10, whichis lost with the new method (Figure 1a and b).2 Similarly, two patients from a recentclinical trial have almost identical levels of dystrophin when assessed using the new
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Please cite as Arechavala-Gomeza et al. Nature Reviews Neurol. doi:10.1038/nrneurol.2012.15-c1method, whereas the original method shows that the average of one sample is increaseddue to a few high measurements (Figure 1c).Some patients have a few intensely dystrophin-positive fibres, whereas others havemore dimly dystrophin-positive fibres, which accounts for the variability in dystrophinexpression in these trials4. To guarantee the optimal evaluation of the response totreatment, it is vital that the maximum amount of information is collected from the verysmall samples available. As image capture methods do not differ,2, 10 only a slightmodification of the method to include several measurements per image would suffice.
Figure 1 Comparison of methods for dystrophin quantification. a. Transverse cryosections of
quadriceps muscle biopsies, immunostained with a dystrophin antibody. b. Intensity profiles of
images in a, captured as an average measurement2 (left) or with multiple measurements10 (right).
c. Two samples from a recent systemic clinical4 trial analysed using average measurement (left)
and multiple measurement (right) Pre-treatment in blue, post treatment in green.
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